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Benchmark dose (BMD) modeling is increasingly used as the preferred approach to deﬁne the
point-of-departure for health risk assessment of chemicals. As data are inherently variable, there is
always a risk to select a model that deﬁnes a lower conﬁdence bound of the BMD (BMDL) that, contrary
to expected, exceeds the true BMD. The aim of this study was to investigate how often and under what
circumstances such anomalies occur under current modeling practice. Continuous data were generated
from a realistic dose–effect curve by Monte Carlo simulations using four dose groups and a set of ﬁve dif-
ferent dose placement scenarios, group sizes between 5 and 50 animals and coefﬁcients of variations of
5–15%. The BMD calculations were conducted using nested exponential models, as most BMD software
use nested approaches. ‘‘Non-protective’’ BMDLs (higher than true BMD) were frequently observed, in
some scenarios reaching 80%. The phenomenon was mainly related to the selection of the non-sigmoidal
exponential model (Effect = a  ebdose). In conclusion, non-sigmoid models should be used with caution as
it may underestimate the risk, illustrating that awareness of the model selection process and sound iden-
tiﬁcation of the point-of-departure is vital for health risk assessment.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Health risk assessment of chemicals is the process of character-
izing and quantifying the potential adverse health effects associ-
ated with exposure to chemicals (NRC, 1994). Characterizing the
hazardous properties of a chemical agent in quantitative terms in-
cludes selection of a relevant dataset and description of the dose–
effect relationship for the critical effect. With the exception of
direct acting carcinogenic substances it is assumed that there are
some doses that do not result in adverse effects (Dybing et al.,
2002; Edler et al., 2002). An important part of the risk assessment
is therefore the process of ﬁnding the threshold dose, below which
toxicity is not expected. Experimental data are used to describe the
dose–effect relationship and to deﬁne the point of departure (POD),
for development of reference or limit values such as acceptable or
tolerable daily intakes, occupational exposure limits, derived noeffect levels, population adjusted doses and acute guidance values.
Such values are key elements in the regulatory process to deﬁne
the quality standards for water, food, air, work places etc. It is
therefore of vital interest that the methods used to interpret toxi-
cological data are continuously examined and further developed to
ensure the best use of data.
Traditionally, the no-observed-adverse-effect level (NOAEL)
method is used as the POD in regulatory toxicity testing. The
NOAEL is deﬁned as the highest tested dose that does not give an
effect which is statistically signiﬁcant from that in the control
group (WHO, 1999). The benchmark dose (BMD), on the other
hand, is deﬁned as the dose that results in a predeﬁned effect level,
ideally at a level that is close to, but not yet, adverse. The BMD
method is suggested as a more scientiﬁcally sound alternative to
the NOAEL method and has been implemented in most regulatory
guidance documents as an alternative or preferred approach
(ECHA, 2008; EFSA, 2009; NAC/AEGL, 2001; Solecki et al., 2005;
USEPA, 1995; WHO, 2009). The BMD method involves ﬁtting a
dose–effect curve, or a set of curves, to the data of interest. A crit-
ical effect size, also referred to as benchmark response, of 5% is of-
ten used as a default for continuous data. The lower bound of the
90% conﬁdence interval of the BMD (BMDL) is suggested to be used
as the POD (Crump, 1984; Sand et al., 2008; USEPA, 2012).
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NOAEL (Allen et al., 1994; Crump, 1984). BMD incorporates infor-
mation on the sample size and the shape of the dose–effect curve.
In addition, BMD values are not constrained to one of the experi-
mental doses, and are less dependent on the study design. Further-
more, high variability in the data and low number of subjects both
tend to result in a higher NOAEL, i.e. a less precautious POD,
whereas the BMDL values tend to become lower, i.e. more precau-
tious, as variability and sample size decreases. BMD aligned design
of experiments have also been suggested as a mean to reﬁne and
reduce animal experiments (Öberg, 2010).
Several dose–effect or dose–response models may be ﬁtted to
the data. Historically, power models and polynomials were used
for continuous data, but in recent years more attention has been gi-
ven to the nested exponential models and nested Hill models that
describe sigmoidal curves that level off at higher doses and are as-
sumed to be more biologically relevant (Sand et al., 2008). Nested
models are included in the most frequently used software for the
statistical analysis of dose–effect data, i.e. BMDS (USEPA, 2013),
developed by the US EPA, and PROAST (Slob, 2011), developed by
the Dutch National Institute for Public Health and the Environment
(RIVM). These models are also recommended by EFSA (EFSA, 2009).
In the nested approaches, the software algorithm moves from sim-
pler (few parameters) to more complex models (more parameters)
according to statistically based decision rules.
In theory, the BMDL should be lower than the ‘‘true’’ BMD in
95%, and higher in 5% of all cases, provided that the correct model
is used. The assumption of model correctness is easily ignored by
risk assessors as a possible source of error. However, considering
the variability of the experimental data, there is an obvious risk
that the use of any approach results in an inappropriate model
selection (i.e. selection of a model that deviates from the true
dose–effect relationship). This might in turn result in a misleading
calculation of the BMD and BMDL. Thus, there is a risk that esti-
mated BMDL values become higher than the true BMD far more
frequently than the expected 5%. A high frequency of ‘‘false’’ or
‘‘non-protective’’ BMDLs would be unfortunate, as the resulting
POD would then be less protective than assumed. The aim of this
study was to use simulated data to investigate how frequently
and under what circumstances non-protective BMDL values occur
with continuous data, and to quantify the possible impact on quan-
titative health risk assessment.2. Materials and methods
The occurrence of non-protective BMDLs was investigated using
one ﬁxed dose–effect curve with added variability. The OECD stan-
dard of four dose group was tested, i.e. control, low, medium and
high, with logarithmic dose spacing (1, 3, 10). Five dose-placement
scenarios (A–E) were tested, in these the doses were placed onFig. 1. Dose placement scenarios used in the Monte Carlo generation of dose–effect data
where the highest dose was equal to the EC50 to the highest dose placement (dose placem
indicate the 95% conﬁdence interval of the group means with 20 animals/group and a co
group and CVs of 5% and 15%.different parts of the dose–effect curve, while maintaining the 1–
3–10 dose spacing. Different dose placements and variabilities
were used to take into account that in a real toxicity study the po-
tency of the tested substance is not known beforehand and that
several similar endpoints with different sensitivity and variability
may be evaluated from the same study.2.1. Scenarios
Five different dose placement scenarios with the same relative
logarithmic (control, 1, 3, 10) dose spacing were used, ranging from
a scenario with the three dose groups at the low end of the dose–
effect curve where the highest dose were corresponding to a dose
that caused 50% of the maximum effect (ED50) to a scenario with
the dose group at the high end where the lowest dose correspond-
ing to ED50 (Fig. 1). Simulations were performed with 5, 10, 20 and
50 animals per dose group. Both the number of dose groups and
the number of animals per group were chosen according to stan-
dard OECD Guidelines for the testing of chemicals (OECD, 2012).2.2. Generation of dose–effect data
1200 datasets were generated for each of the ﬁve scenarios by
Monte Carlo simulation. The effect size of each individual in these
datasets was calculated with the exponential model (as described
by Moerbeek et al., 2004):
y ¼ a ðc  ðc  1Þ  ebxd Þ þ e ð1Þ
where (y) is the effect and (x) is the dose. The background effect (a)
and the shape parameter (d) were both set to 1, whereas the max-
imum effect (c) was set to 1.3. These values are realistic (Slob and
Setzer, 2013) and the same values for (a) and (c) were also used
by Slob et al. (2005). The potency parameter (b) was set to 0.231
to obtain an ED50 value of 3. The critical effect size was set to 5% in-
crease over background corresponding to a ‘‘true’’ BMD of 0.79. A
log-normally distributed residual error (e), was added to each sam-
ple to account for inter-individual variability and measurement er-
ror. The error was deﬁned as
ðe ¼ erZÞ ð2Þ
where r is the standard deviation of the logarithm and Z is the stan-
dard normal deviate. Coefﬁcients of variation of 5%, 10% or 15%,
were investigated, by varying r. The choice of CVs was based on
earlier studies (Slob et al., 2005), where it was noted that median
CV where around 10% in historical data analyzed with the bench-
mark dose approach.. The dose placements ranged from the lowest dose placement (dose placement A)
ent E) where the dose in the lowest dose group was equal to the EC50. The error bars
efﬁcient of variation (CV) of 10%. Data were also generated for 5, 10 and 50 animals/
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The BMD calculations were conducted using the nested expo-
nential models described by Slob (2002) (Fig. 2). The models are
termed nested as the simpler models are derived from the more
complex ones by setting the parameters (b), (c) and/or (d) to zero
or one.
A commonly used model selection procedure suggested by Slob
(2002), henceforth called the standard method, was used to select
the most appropriate model for the BMD calculations. First, if no
higher model gave a better ﬁt than model 1, it was concluded that
there was no dose–effect trend and no BMDL was calculated. Sec-
ond, if a dose–effect trend was observed, model 2 was compared to
models 3, 4 and 5 and the most favorable model according to like-
lihood ratio tests was then chosen. This likelihood ratio tests penal-
izes models with more parameters in order to reduce the risk of
overparameterization and is implemented in both PROAST and
BMDS as a tool for model selection within nested models.
An alternative model selection procedure was tested for com-
parison. This procedure was based on the same set of nested expo-
nential models and selection via the likelihood ratio test. However,Fig. 2. The nested exponential dose–effect models used in the Benchmark-Dose calcula
Model 1 is obtained frommodel 2 by setting b = 0, model 2 is obtained frommodel 3, 4 or
(base line, steepness, maximum) will depend on the choice of model parameters.it did not allowmodel 2 as ﬁnal choice of model. If model 2 was the
selected model using the standard method, the alternative method
selected a model with a ceiling parameter (model 4 or 5) instead.
In the model ﬁtting process some restriction was applied to the
model parameters. The parameter (d) was restricted to P1 in line
with the parameter restrictions in the BMDS software. The param-
eter (c) was limited to values between 1.055 and 1000 as they are
defaults in PROAST (v28.1) if a critical effect size of 5% is used.
2.4. Global and local goodness of ﬁt tests
A global and a local goodness of ﬁt test were applied to the re-
sults of the model ﬁtting. The local and global goodness of ﬁt tests
are available in some BMD software to guide the selection of a rea-
sonable model. The global ﬁt of the selected model was evaluated
by comparison with the ﬁt of the full model according to the like-
lihood ratio test with a p-value 60.1. The full model estimates the
mean and the variance of the effect for each dose group without
making any interpolations between the dose groups. While it is
not possible to calculate a BMDL by the full model, it may still be
used as a reference.tions (Slob, 2002). The variables (x) and (y) represent dose and effect, respectively.
5 by setting c = 0 and/or d = 1. The axes have no numerical values, as the curve shape
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the estimated effects:
scaled residual ¼ jlobserved group mean  lpredicted group meanj
SEMestimated
ð3Þ
where l is the mean effect at a speciﬁc dose and the SEM is the stan-
dard error of the mean of the effect at that dose, both being esti-
mated on log-scale. If the full model is signiﬁcantly better than
the selected model or if a scaled residual isP2, the selected model
is generally recommended to be questioned by the assessor per-
forming the benchmark dose analysis. In our study, a model was
still selected regardless of whether the full model was signiﬁcantly
better than the selected model or had a scaled residual ofP2, but it
was highlighted that the calculated BMDL might be unreliable.2.5. BMDL-calculations
The lower bound of the two-sided 90% conﬁdence intervals for
the BMD was deﬁned as the BMDL and compared to the ‘‘true’’
BMD. In general, a BMDL is considered to be conservative and
health protective as it is interpreted as an underestimate of the
true BMD and, hence, an overestimate of the health risk. Following
the deﬁnition of BMDL, the BMDL/trueBMD-ratio is expected to fall
below 1 in 95% of the cases. Conversely, the occurrence of ratios
above 1 in more than 5% of the cases suggests that the health risk
is underestimated.
Different methods can be used to estimate the conﬁdence inter-
val for the BMD. In this paper the likelihood ratio method was used
in all simulations as it is the most common for calculating conﬁ-
dence intervals for the BMD. Since the likelihood ratio method
can give unreliable results in some situations (Moerbeek, 2004),
the bootstrap method was used to verify the occurrence of non-
protective BMDLs from the likelihood ratio method. The bootstrap
method was implemented as described in Moerbeek et al. (2004).
In addition to the BMD estimates, NOAEL values for all simula-
tions were calculated by multiple comparisons of the effects in theFig. 3. The frequency of simulations with non-protective BMDLs ( BMDLtrue BMD > 1), where BM
dose and true BMD is the ‘‘true’’ benchmark dose. The BMDL values were calculated us
models. Dose–effect data were generated by Monte Carlo simulation from a predeﬁned d
of the columns indicate the number of animals per dose group. The lighter foremost codifferent groups by a two-sided Dunnett’s test at the 5% signiﬁ-
cance level. The Dunnett’s test was performed on log-scale since
the data were log-normally distributed. If the middle dose group
was the only dose that had an effect that was signiﬁcantly different
from controls, the low dose group was still considered as the
NOAEL even though the high dose group was not different from
controls. It was also noted how often the NOAEL exceeded the true
BMD.2.6. Software
The Monte Carlo simulations were carried out using R (ver-
sion 2.13.1) (R Core Development Team, 2011).The Dunnett’s
tests were performed using the glht function in the multcomp
package (Hothorn et al., 2008) and the BMD calculations were
performed using PROAST version 28.1 (Slob, 2011) with some
added code. The calculations were parallelized using the snowfall
package (Knaus, 2010). The research code can be provided upon
request.3. Results
The percentage of BMDLs found to be higher than the ‘‘true’’
BMD, hereafter called non-protective BMDLs, occurred in more
than the expected 5% in nearly all tested scenarios. The frequency
of non-protective BMDLs was clearly related to the assumed vari-
ability as well as the dose placement scenario (Fig. 3, Table 1). In
general, higher frequencies of non-protective BMDLs were associ-
ated with higher variability and dose-placements in the lower
end of the dose–effect curve. Thus, in the simulation with medium
variability (CV = 10%), doses placed in the low region of the dose–
effect curve (scenario A), and a high number of animals (50/group)
the percentage of non-protective BMDLs was 76%. Maintaining all
settings but decreasing the number of animals to 5 resulted in a
decreased number of non-protective BMDLs down to 5%, instead
the frequency of no dose–effect trend observed increased fromDL is the lower bound of the two-sided 90% conﬁdence interval of the benchmark
ing either the standard or alternative procedure for selecting between ﬁve nested
ose–effect curve with added lognormal variation (CV) of 5%, 10% or 15%. The shades
lumns represent 50 animals/group, followed by 20, 10 and 5 animals/group.
Table 1
Distribution of BMDLtrue BMD-ratios, where BMDL is the lower bound of the two-sided 90%
conﬁdence interval of the benchmark dose calculated using the standard procedure
with nested exponential models. Dose–effect data were generated by Monte Carlo
simulation from a predeﬁned dose–effect curve with a coefﬁcient of variation of 10%.
The dose placement scenarios (A–E) are illustrated in Fig. 1. Additional tables for all
scenarios can be found in Supplements.
Dose scenario Animals/group 1 < Ratio 6 3 (%) 3 < Ratio 6 10 (%)
A 5 4.9 0.6
10 23 0.3
20 48 0.4
50 76 0.4
B 5 74 0.4
10 80 0.4
20 67 0.0
50 35 0.0
C 5 68 1.8
10 58 1.2
20 33 0.5
50 8.2 0.0
D 5 18 27
10 5.4 15
20 4.7 2.2
50 6.1 0.0
E 5 3.8 14
10 5.5 2.3
20 7.8 0.0
50 6.8 0.0
J. Ringblom et al. / Regulatory Toxicology and Pharmacology 69 (2014) 171–177 1750% to 32%. When doses were placed closer to the center of the
dose–effect curve (scenarios B and C), the frequency of non-protec-
tive BMDLs ranged from 8% (scenario C, 50 animals/group) to 80%
(scenario B, 10 animals/group). When doses were placed in the
upper region of the dose–effect curve (scenarios D and E), the
non-protective BMDLs were not as frequent compared to the situ-
ation at lower doses, ranging from 6% (scenario D, 50 animals/
group) to 46% (scenario D, 5 animals/group).
As expected, non-protective BMDLs were generally less fre-
quent at low variability, as compared to the situation with higher
variability. Still, as high as up to 84% were non-protective for dose
placement A and 20 animals/group using a CV of 5% (Fig. 3). The
simulations with higher variability (CV = 15%) generally showed
the same tendencies under the standard procedure as those with
medium variability. However, at higher dose placement (scenarios
D and E) the non-protective BMDLs were more frequent than in the
simulations with medium variability.
More than 90% of the simulations with non-protective BMDLs,
calculated using the standard procedure for model selection,Fig. 4. The frequency of simulations with non-protective NOAELs ( NOAELtrue BMD > 1), where tr
Carlo simulation from a predeﬁned dose–effect curve with added lognormal variation (C
dose group. The lighter foremost columns represent 50 animals/group, followed by 20, 1
ﬁgure is not directly comparable to Fig. 3.passed the extra global and local goodness of ﬁt tests indicating
that these tests alone are not enough to safeguard against the
non-protective BMDLs (data not shown).
In most cases where non-protective BMDLs were observed, the
ratio between the estimated BMDL and the true BMD was usually
within a factor of three (Table 1, Supplement Tables S1, S4 and S7).
In the simulations where the variability was low (CV = 5%), a ratio
between 3 and 10 was rarely observed. As the variability increased
(CV = 10% and 15%), the frequency where the BMDLs exceeded the
true BMD by a factor between 3 and 10 increased, most evident at
dose placements in the upper region (scenario D and E). Under sce-
nario D with a medium variability (CV = 10%), every fourth simula-
tion with 5 animals/group resulted in a ratio above 3 (Table 1). In
the same scenario (i.e. D) with even higher variability (CV = 15%)
and 10 animals/group almost every third simulation showed a ra-
tio above 3.
When the conﬁdence intervals were calculated with the boot-
strap method (tested in parallel), similar frequencies of non-pro-
tective BMDLs were obtained as with the likelihood ratio method
(data not shown), indicating that the observed phenomenon was
not a result of the likelihood ratio method.
With the alternative method, excluding model 2, the frequen-
cies of non-protective BMDLs were never higher than 11% (Fig. 3)
when the conﬁdence intervals were estimated using the likelihood
ratio method. In almost all of these simulations with the alterna-
tive method, the ratio between BMDL and the true BMD was less
than a factor of 3 (Supplement Tables S2, S5 and S8). The frequen-
cies of non-protective BMDLs were closer to the nominal 5% when
the conﬁdence intervals were estimated using the bootstrap meth-
od (data not shown).
The traditional point-of-departure (i.e. NOAEL) was also calcu-
lated and related to the true BMD at the critical effect size of 5% in-
crease from background (Fig. 4). As expected, lower numbers of
animals was related to a decreased probability of detecting any sig-
niﬁcant effect, i.e. no effect detected at any dose. It was observed
that with dose placements in the higher end of the dose–effect
curve and with higher number of animals per dose group the prob-
ability of only detecting a LOAEL increased substantially. In addi-
tion, a considerable percentage of the simulations resulted in
NOAEL values that were 3–10 times higher than the true BMD
(Supplemental Tables S3, S6 and S9). In some scenarios, with few
animals per dose group, the NOAEL even exceeded the true BMD
more than tenfold. For example, every second simulation of sce-
nario E with a high variability (CV = 15%) and ﬁve animals per
group resulted in NOAEL values more than ten times higher than
the true BMD, i.e. higher than the effect deﬁned as close to, but
not yet, adverse.ue BMD is the ‘‘true’’ benchmark dose. Dose–effect data were generated by Monte
V) of 5%, 10% or 15%. The shades of the columns indicate the number of animals per
0 and 5 animals/group. Note that NOAELs and BMDLs are different concepts so this
Fig. 6. Example of a simulated dataset using dose scenario C, CV = 10% and 10
animals/group. The upper solid curve is the underlying ‘‘true’’ dose–effect curve and
the lower dashed curve is the estimated curve using model 2 from the nested set of
ﬁve exponential models. The ﬁlled triangles are the geometric mean at each dose
level. The error bars indicate the 95% conﬁdence interval for the geometric mean
effect for a simulated group. The vertical lines indicate (from left to right) the true
BMD, the estimated BMDL, the estimated BMD and the BMDU (the upper bound of
the conﬁdence interval for the BMD) respectively. Note that the estimated BMDL
exceeds the true BMD.
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Theoretically, the BMDL should be higher than the true BMD va-
lue in 5% of all cases, assuming that the selected model describes a
true dose–effect relationship. BMDLs that are higher than the
underlying BMD are unfortunate, as the resulting POD is less pro-
tective than assumed. According to our simulations, the frequency
of non-protective BMDLs (i.e. BMDL/trueBMD > 1) are high under
most scenarios and reach as high as 80% under some scenarios
(Fig. 3). Our results challenge the interpretation of BMDL values
as being equivalent to conservative estimates of no-effect thresh-
old levels. For the non-protective BMDLs, the ratios between the
BMDL and the true BMD were in most cases found to be within a
factor of three. However, in scenarios with few animals per group
and dose placements in the upper region of the dose–effect curve,
the ratios ranged from 3 to 10 in 31% of the simulations, thereby
clearly underestimating the risk at the POD.
Because of the increased awareness of the BMD approach as a
preferred method for establishing the POD in quantitative risk
assessment, it is of interest that the model selection procedure
used to interpret toxicological data is continuously examined and
further developed, thereby to ensure the best use of data. Derived
BMDL values that frequently underestimate the risk for health ef-
fects are certainly unsatisfactory.
We evaluated the underlying reason for non-protective BMDLs
in our simulations by tracking which equation was used following
a common algorithm for model selection. Simulations resulting in
non-protective BMDLs were found to be strongly associated with
selection of the second exponential model in the nested structure
for the BMD calculations. In 60% of the simulations with scenario
C, 10 animals/group and an assumed CV of 10%, the BMDLs were
non-protective. In almost all these situations, model 2 was the se-
lected model (for example see Fig. 5). Similar results (i.e. model 2
results in non-protective BMDLs) were also observed with the
other scenarios (data not shown). Fig. 6 illustrates how the selec-
tion of model 2 can result in falsely high BMDL-values; a single
simulation in which model 2 is selected as the base for BMDL esti-
mates are compared with the true dose–effect curve (scenario C,
CV = 10% and 10 animals/group). Model 2 does not include a
parameter that enables the dose–effect curve to level-off at high
doses. In the standard procedure for model selection, model 2 is
frequently selected when there is insufﬁcient information to
identify the effect plateau at high doses. This can explain theFig. 5. The distribution of BMDLtrue BMD-ratios, where BMDL is the lower bound of the 90%
conﬁdence interval of the benchmark dose and true BMD is the ‘‘true’’ benchmark
dose. BMDLs were calculated by the standard procedure for model selection using
1200 sets of dose–effect data with a coefﬁcient of variation(CV) of 10% generated by
Monte Carlo simulation with dose placement scenario C and 10 animals/group. The
lighter grey striped bars shows the ratio for the simulations where model 2 was the
selected model. The darker grey bars shows the ratios for the model 3, 4 or 5. The
vast majority of simulations resulting in non-protective BMDL values (BMDL/
trueBMD > 1) are associated with the selection of model 2.observation in Fig. 3, where non-protective BMDLs were mostly
found in scenarios with few animals and doses placed in the low
effect region.
Larger groups generally resulted in fewer non-protective
BMDLs, with low dose placements (scenario A) as the exception
(Fig. 3). Dose placement scenario A resulted in a situation where
the non-protective BMDLs were most frequent in the simulations
with more animals. As the conﬁdence interval of the BMD became
narrower with a high number of animals, the probability of a non-
protective BMDL also increased. However, as the conﬁdence inter-
vals were narrow, the ratio between the estimated BMDL and the
true BMD was only slightly higher than one. The conﬁdence inter-
vals also got narrow with more animals at higher dose placements,
but in those cases the high number of animals also increased the
frequency of cases where the plateau was identiﬁed (i.e. model 2
was not selected) leading to lower BMDL values. However, in sim-
ulations when the plateau effect was not identiﬁed (i.e. model 2
was selected), the BMDL/trueBMD-ratio was often found to be >3
(see Supplement Table S7 for example).
The observation that BMDLs from the simulated data can be
higher than the ‘‘true’’ BMD in a large number of simulations has
previously been mentioned in a study on continuous data (Slob
et al., 2005) and investigated in a study on quantal data (West
et al., 2012). Slob et al. (2005) mentioned that non-protective
BMDLs occurred frequently when the total number of animals in
a study was 50 or less and the residual variation was large
(CV = 18%). The potential impact on risk assessment was, however,
not further commented on by the authors. The present simulations
show high frequencies of non-protective BMDLs with lower varia-
tion (CV = 5% and 10%) and with more animals (up to 200, i.e. 50
per dose group).
West et al. (2012) recently showed that the frequencies of non-
protective BMDLs can be as high as 100% for quantal data. They
concluded that the true extra risk at the BMDL under an incorrectly
selected model can surpass the target benchmark response, expos-
ing the potential dangers of traditional strategies for model selec-
tion when calculating BMDs and BMDLs. Our conclusions on
continuous data are similar, although the fractions of non-protec-
tive BMDLs in our study seem less worrying than those presented
by West et al. (2012). It has to be noted that the case with 100%
non-protective BMDLs in their study comes from a situation where
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taking into account that the ﬁtted model might be incorrect. Fur-
thermore, local ﬁt measures such as scaled residuals were not ta-
ken into account. Therefore, the frequency of non-protective
BMDLs might be misleading, since models with poor local ﬁt is
not likely to be accepted by an assessor.
In the present study, we assume the true dose–effect curve for
continuous data to be sigmoid on the log dose scale and thus to le-
vel off at high doses. This is in accordance with most biological
observations, from enzyme kinetics to population models of infec-
tious diseases and has been conﬁrmed in a recent study on a vari-
ety of endpoints (Slob and Setzer, 2013). A plateau might of course
not be reached within the studied dose range. However, with the
current use of nested models, it is assumed that there is no ceiling
effect unless there is clear evidence of the opposite. An alternative
approach, that in our opinion is more biologically plausible, is to
assume that a plateau exist unless there are good reasons to be-
lieve the opposite. If prior knowledge about a plateau is available
this should be taken into account in the BMD modeling. One pos-
sibility would be to use models with scientiﬁcally justiﬁed narrow
bounds for the plateau parameter. Another possibility to identify
the plateau level would be to ﬁt the dataset of interest simulta-
neously with historical data on the same endpoint but with other
substances, as done by Slob and Setzer (2013).
Even though it might make sense from a biological viewpoint to
always include a plateau parameter in the dose–effect analysis, this
approach can be problematic if all doses appear at the lower part of
the dose effect curve. Thus, if it is of special importance to deter-
mine the plateau parameter, for instance in order to calculate the
ED50, the study should obviously include dose groups that inform
about the plateau. Also, including an unrestricted plateau parame-
ter does increase the risk of obtaining BMDLs that are too high as a
result of numerical problems in the estimations. If the proﬁle like-
lihood method is used to calculate conﬁdence intervals it is partic-
ularly important to examine the proﬁle likelihood curves before
accepting a BMDL. It is also possible to estimate the conﬁdence
interval using another method, such as the bootstrap method.
However, the bootstrap method is more time-consuming than
the likelihood ratio method.
None of the studies observing falsely high BMD estimates (Slob
et al., 2005; West et al., 2012, present study) take into account that
in a real life situation the risk assessor should always make a visual
inspection of the BMD curves and their ﬁt to the experimental data.
Yet, even if a model ﬁts the data perfectly it does not necessarily
mean that that model describes the underlying reality equally well.
In fact, without knowing the ‘‘true’’ dose–effect relationship it is
impossible to observe how well the estimated BMD describe the
risk for health effects.
Since the NOAEL approach is still used in many regulatory set-
tings, it was evaluated in comparison with the true BMD at an effect
size of 5%. Our simulations clearly illustrate the disadvantages with
the NOAEL approach. Thus, the NOAEL value (in relation to the true
effect level) is highly dependent ondose placement, especiallywhen
the variability is high and the number of animals is low. The NOAEL
frequently exceeds the true BMD, being higher in as many as 96% of
the simulations in one scenario. This supports the notion by several
agencies that the NOAEL approach should be used with caution and
that the BMD can be considered as a more robust alternative (EFSA,
2009; NAC/AEGL, 2001;WHO, 2009) and that the NOAEL should not
be interpreted and used as a no-effect-level, especially if the num-
bers of animals are low and/or the variability is high.
In conclusion, the current practice of using nested model selec-
tion in BMD modeling of continuous data can result in high fre-
quencies of falsely high BMDL estimates eventually resulting in
non-protective POD for quantitative risk assessment. The phenom-
enon is mainly related to the selection of a non-sigmoidalexponential model. Such models should be used with caution as
they may underestimate the risk, illustrating that awareness of
the model selection process and sound identiﬁcation of the
point-of-departure is vital for health risk assessment.
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